Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial

doi:10.3748/wjg.v16.i25.3133

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 25

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7928)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-5) series.

Item

Count

PDF

655

HTML

6900

Figures (1-3)

199

Tables (1-5)

174

Sum=7928

Jul 7, 2010 (publication date) through Sep 22, 2024

Times Cited of This Article

Times Cited (80)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Original Article

World J Gastroenterol. Jul 7, 2010; 16(25): 3133-3143
Published online Jul 7, 2010. doi: 10.3748/wjg.v16.i25.3133

Table 3 Efficacy in the ITT population

Characteristic	FOLFOX6 plus cetuximab (arm A, n = 77)	FOLFIRI plus cetuximab (arm B, n = 74)
PFS
Events, n (%)	61 (79)	59 (80)
Median¹, mo (95% CI)	8.6 (6.3-9.7)	8.3 (7.4-8.7)
Log rank P-value	0.7375
Hazard ratio (95% CI)	1.06 (0.74-1.52)
PFS rate¹, % (95% CI)
3 mo	92 (85-98)	78 (68-88)
6 mo	69 (58-80)	69 (58-80)
9 mo	45 (33-58)	34 (23-46)
12 mo	18 (8-27)	18 (8-27)
Overall survival
Events, n (%)	54 (70)	50 (68)
Median¹, mo (95% CI)	17.4 (14.9-22.6)	18.9 (14.7-23.9)
Logrank P-value	0.9230
Hazard ratio² (95% CI)	0.98 (0.67-1.44)
Survival rate¹, % (95% CI)
9 mo	79 (70-88)	79 (70-89)
12 mo	70 (60-80)	71 (60-81)
18 mo	46 (35-57)	53 (42-65)
24 mo	33 (22-44)	38 (26-50)
Best overall response, n (%)
CR	2 (3)	6 (8)
PR	31 (40)	27 (36)
SD	31 (40)	24 (32)
PD	6 (8)	9 (12)
NE	7 (9)	8 (11)
Objective response rate, n (%)	33 (43)	33 (45)
95% CI	32-55	33-57
Odds ratio (95% CI)	0.93 (0.49-1.77)

¹Median time and rates are based on Kaplan-Meier estimates;

²Hazard ratio and corresponding 95% CI based on unadjusted Cox proportional hazard model: hazard rate FOLFIRI plus cetuximab divided by hazard rate FOLFOX6 plus cetuximab. CR: Complete response; NE: Not evaluable; PD: Progressive disease; PFS: Progression-free survival; PR: Partial response; SD: Stable disease.

Citation: Ocvirk J, Brodowicz T, Wrba F, Ciuleanu TE, Kurteva G, Beslija S, Koza I, Pápai Z, Messinger D, Yilmaz U, Faluhelyi Z, Yalcin S, Papamichael D, Wenczl M, Mrsic-Krmpotic Z, Shacham-Shmueli E, Vrbanec D, Esser R, Scheithauer W, Zielinski CC. Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. World J Gastroenterol 2010; 16(25): 3133-3143
URL: https://www.wjgnet.com/1007-9327/full/v16/i25/3133.htm
DOI: https://dx.doi.org/10.3748/wjg.v16.i25.3133